These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8714615)
1. Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Piro LD Semin Hematol; 1996 Jan; 33(1 Suppl 1):34-9. PubMed ID: 8714615 [No Abstract] [Full Text] [Related]
2. Cladribine for the treatment of indolent non-Hodgkin's lymphomas. Hoffman MA Semin Hematol; 1996 Jan; 33(1 Suppl 1):40-4. PubMed ID: 8714616 [No Abstract] [Full Text] [Related]
3. 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies. Lauria F Haematologica; 1992; 77(6):443-5. PubMed ID: 1363233 [No Abstract] [Full Text] [Related]
4. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071 [TBL] [Abstract][Full Text] [Related]
7. [Cladribine]. Ogura M Gan To Kagaku Ryoho; 2003 Feb; 30(2):309-17. PubMed ID: 12610885 [TBL] [Abstract][Full Text] [Related]
8. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Saven A; Piro LD Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962 [TBL] [Abstract][Full Text] [Related]
9. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Laurencet FM; Zulian GB; Guetty-Alberto M; Iten PA; Betticher DC; Alberto P Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762 [TBL] [Abstract][Full Text] [Related]
10. The role of cladribine in the treatment of lymphoid malignancies. Nelson MC; Hogan DK Oncol Nurs Forum; 1995 Oct; 22(9):1395-400. PubMed ID: 8539180 [TBL] [Abstract][Full Text] [Related]
11. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067 [TBL] [Abstract][Full Text] [Related]
12. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma. Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559 [No Abstract] [Full Text] [Related]
13. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. King KM; Younes A Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023 [TBL] [Abstract][Full Text] [Related]
14. Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine. Krishna VM; Carey RW; Bloch KJ N Engl J Med; 2003 May; 348(20):2045-6. PubMed ID: 12748329 [No Abstract] [Full Text] [Related]
16. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment with 2-chlorodeoxyadenosine of secondary lesions of the central nervous system in low-grade lymphoid malignancies. deCataldo F; Baudo F Am J Hematol; 2002 Aug; 70(4):332-3. PubMed ID: 12210819 [No Abstract] [Full Text] [Related]
19. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K; Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902 [TBL] [Abstract][Full Text] [Related]
20. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma. Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308 [No Abstract] [Full Text] [Related] [Next] [New Search]